2004 OCT 12 - (NewsRx.com & NewsRx.net) -- The emerging role of human papillomavirus (HPV) testing as a standard of care in cervical cancer screening was highlighted at the annual meeting of the College of American Pathologists (CAP) in Phoenix, Arizona.
Two symposia titled "Current Issues in Gynecologic Cytology" and "Squamous Lesions and Adequacy Issues in Cervical Cytology" reviewed data supporting the combined use of a Pap test and an HPV test in women 30 years of age and older.
Digene Corp. (DIGE) markets the DNAwithPap Test, the only U.S. Food and Drug Administration-approved adjunctive screening test for HPV, which is the cause of virtually all cases …
No comments:
Post a Comment